Iridex (IRIX) Short term Debt (2020 - 2021)

Iridex (IRIX) recorded quarterly Short term Debt of $2.2 million in Q2 2021, up 74.94% quarter-over-quarter from $1.2 million in Q1 2021.

Iridex (IRIX) Short term Debt (2020 - 2021) Analysis & Trends

Iridex's Short term Debt history runs 2 years deep, the most recent figure standing at $2.2 million for Q2 2021.

In Q2 2021, Short term Debt changed N/A year-over-year to $2.2 million; the TTM figure through Apr 2021 stood at $2.2 million (changed N/A YoY), while the FY2021 annual figure was $1.2 million, changed N/A from the prior year.
Short term Debt was $2.2 million for Q2 2021 at Iridex, up from $1.2 million in the prior quarter.
In the past five years, Short term Debt ranged from a high of $2.2 million in Q2 2021 to a low of $1.2 million in Q1 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Abbott Laboratories	154.42 Bn	147.76 Bn	6.27 Bn
2	Stryker	118.12 Bn	115.25 Bn	3.81 Bn
3	Medtronic	101.72 Bn	93.55 Bn	5.76 Bn
4	Boston Scientific	67.19 Bn	65.98 Bn	3.61 Bn
5	Edwards Lifesciences	50.69 Bn	47.02 Bn	1.29 Bn
6	Koninklijke Philips	29.38 Bn	26.07 Bn	2.07 Bn
7	Dexcom	28.09 Bn	26.97 Bn	750.30 Mn
8	GE HealthCare Technologies	28.08 Bn	26.02 Bn	1.98 Bn
9	Steris	19.80 Bn	19.37 Bn	697.10 Mn
10	Iridex	19.91 Mn	15.31 Mn	4.74 Mn

Download Data